Impact of smoking and nicotine addiction on HbA1c levels and diabetic microvascular complications by Akkuzulu, Hüseyin et al.
 original article iSSn 2450–7458
1
Hüseyin Akkuzulu, Cenk Aypak, Ayşe Özdemir, Süleyman Görpelioğlu
Department of Family Medicine, University of Health Sciences, Ankara Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
Impact of smoking and nicotine addiction 
on HbA1c levels and diabetic microvascular 
complications
ABSTRACT
Introduction. In this study we aimed to determine 
whether a difference in complications between smok-
ers and non-smokers exists in type 2 diabetes mellitus 
(T2DM) and to evaluate if there is a correlation between 
microvascular complications and Fagerström test score.
Material and methods. Patients with T2DM who at-
tended the family medicine outpatient clinics were 
enrolled in the study. Smokers and non-smokers were 
compared according to their metabolic outcomes and 
presence of microvasculer complications. The level of 
smoking addiction was determined by Fagerström Test 
for Nicotine Dependence.
Results. Fasting blood glucose (FBG), low-density 
lipoprotein, systolic and diastolic blood pressures 
were found to be higher in smokers. The presence of 
neuropathy was significantly higher in smokers. The 
presence of retinopathy rate increased with increasing 
level of smoking addiction. The nicotine dependence 
test score were found to be positively correlated with 
HbA1c and FBG levels whereas, negatively correlated 
with body mass index among smokers.
Conclusions. Assessing the cigarette smoking status of 
diabetic patients at the initial clinic visit and indicating 
the importance of smoking cessation should be the 
essential part of diabetes follow up program. (Clin 
Diabetol 2020; 9)
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Introduction
Type 2 diabetes mellitus (T2DM) is a major health 
and socioeconomic problem for the community. Ac-
cording to the World Health Organisation’s (WHO) data 
422 million adults were living with DM in 2014 [1]. The 
number of adults with DM reached 451 million in 2017 
and keeps increasing [2]. It is predicted that 642 million 
people will have DM and 481 million people will have 
impaired glucose tolerance by the year 2040 [3]. DM 
directly caused 1.6 million deaths in 2016 [4].
More than 1.1 billion people worldwide aged 
15 years or older smoked tobacco in 2016 [4]. 
Smoking is the utmost known modifiable risk fac-
tor for many chronic diseases such as cardiovascu-
lar disease, chronic obstructive lung disease, and 
T2DM. Association between smoking and T2DM was 
investigated in previous studies [5]. According to 
a recent study, genetic polymorphisms in the nico-
tinic acetylcholine receptor genes may contribute to 
the association between smoking and T2DM [6]. 
Smoking is an independent risk factor for T2DM and 
both active smoking and exposure to passive smoke 
increase the risk of T2DM [7]. Compared with non- 
-smokers with no exposure to passive smoke, there is 
an increased risk of T2DM among nonsmoker exposure 
with passive smoke [8]. Furthermore, smoking is found 
to be a risk factor for chronic complications of T2DM 
such as progression of diabetic nephropathy, peripheral 
polyneuropathy and diabetic retinopathy [9–13].
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This study aims to determine whether a difference 
in microvascular complications between diabetic pa-
tients who are smokers and non-smokers exists and to 
evaluate if there is a correlation between microvascular 
complications and smoking addiction.
Methods
Study population
T2DM patients who attended the family medicine 
outpatient clinics of a referral hospital were enrolled 
consecutively in the study. Patients with gesta-
tional diabetes, secondary diabetes; retinopathy, 
nephropathy or neuropathy not caused by diabetes; 
oncologic, inflammatory, immunologic or neuropsy-
chiatric disease, ex-smokers and patients younger 
than 18 were excluded. A questionnaire regarding 
medical history and lifestyle factors was used during 
the clinic examinations.
Data collection and measurements
A structured checklist was used to record patients’ 
demographics and laboratory data. We measured 
height to the nearest centimeter, weight to the nearest 
0.5 kg, and systolic blood pressure (SBP) and diastolic 
blood pressure (DBP) to the nearest mm Hg. Blood 
pressure was measured with a standard mercury 
sphygmomanometer while the patient was sitting 
after resting for 10 minutes and a mean of 3 readings 
was recorded. The subjects had their body weight 
(kg) assessed in the morning after overnight fasting. 
Bodyweight was measured using digital scales with the 
subjects only wearing underwear. BMI was calculated 
as weight (kg) divided by height (m) squared.
Smokers’ severity of dependence was determined 
with The Fagerström Nicotine Dependence Test. In ac-
cordance with test scores, subjects were considered 
as minimally dependent (4 points or less), moderately 
dependent (5 to 7 points) and highly dependent (8 to 
10 points).
Patients were examined by an ophthalmologist 
with an ophthalmoscope to determine retinopathy. Mi-
croaneurysm, retinal hard exudates, retinal edema, and 
retinal new vessels are evaluated positively for retin-
opathy. Blood creatinine levels, glomerular filtration 
rate (GFR) and elevated albuminuria of > 300 mg/24 h 
with concurrent presence of diabetic retinopathy and 
absence of signs of other forms of renal disease were 
used to evaluate nephropathy [14]. GFR is calculated 
with the CKD-EPI equation: GFR = 141 × min (SCr/k, 1)a 
× max (SCr/k, 1)–1.209 × 0.993age × 1.018 (for women) 
(SCr is serum creatinine [mg/dL], k is 0.7 for females 
and 0.9 for males, a is –0.329 for females and –0.411 
for males, min indicates the minimum of SCr/k or 1, 
and max indicates the maximum of SCr/k or 1). Pa-
tients with GFR < 60 ml/min, > 300 mg albumin 
levels in 24-hour urine sample were diagnosed with 
nephropathy. 
Patients were assessed for neuropathy using 
their medical history and examination. Symptoms 
especially worsened or occurring mostly during the 
night such as pain, dysesthesias (unpleasant sensa-
tions of burning and tingling), numbness and loss of 
protective sensation were considered as neuropathy 
symptoms. Comprehensive physical examination 
was performed to examine neuropathy include 
muscle power and tone examination, vibration 
perception examination with 120–200 Hz diapason, 
temperature and pinprick sensation examination, 
proprioception examination, 10-g monofilament 
to assess light-touch perception and ankle reflexes 
examinations are done to detect neuropathy [15]. 
Any abnormal examination result was evaluated as 
neuropathy. Electroneurography was not performed. 
Patients’ exercise and diabetes educational sta-
tus were assessed. Patients who exercised at least 
30 minutes per day and 3 to 7 days of the week 
were assessed as performing exercise regularly. Pa-
tients who had already been informed by a health 
professional including general practitioner or family 
physician about the course of T2DM, its complications 
and treatment options were considered educated. 
ADVIA 2400 Chemistry Systems/SIEMENS device 
was used to detect fasting plasma glucose (FBG), 
postprandial plasma glucose (PBG), total cholesterol 
(TC), low-density lipoprotein (LDL), high-density li-
poprotein (HDL), triglyceride (TG), protein levels in 
24-hour urine samples. HbA1c levels are detected by 
(HPLC) Hb9210/PREMIER device which used boronate 
affinity technology. 
Statistical analyses 
We used IBM SPSS version 22 statistics for statistical 
analysis. Data’s compatibility with normal distribution 
was determined by the Kolmogorov-Smirnov test. Com-
parisons between groups were made using Student’s t 
test (for continuous variables) and the Chi-square test 
(for categorical variables). All values are expressed as 
the mean ± SD or number (%). We assumed p < 0.05 
indicated significant differences. 
Results
A total of 210 patients with T2DM (64.3% men) 
were enrolled into the study. The mean age of the 
patients was 49.7 ± 14.5, mean BMI was 26.2 ± 4.4 
kg/m2 and the mean T2DM duration was 8.3 ± 5.9 
years. A total of 70 (33.3%) participants were active 
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smokers. Their mean smoking duration was 26.5 
± 17.5 pack-year. Comparison of demographical 
and clinical features of smokers and non- smokers 
are presented in Table 1. SBP (p = 0.05) and DBP 
(p = 0.001), FBG (p = 0.008) and LDL (p = 0.042) 
were found to be higher in smokers, respectively. 
Although the mean HbA1c was found to be higher 
in smokers, it was not statistically significant. There 
were no significant differences between smokers and 
non-smokers in terms of their antidiabetic medications 
(Table 2).
The presence of neuropathy was significantly 
higher in smokers (Table 3). The presence of retinopathy 
rates increased with an increasing level of smoking ad-
diction (p = 0.015) (Table 4). The nicotine dependence 
test score was found to be positively correlated with 
HbA1c and FBG levels whereas, it negatively correlated 
with body mass index among smokers (p = 0,042) 
(Table 5).
Discussion
Association between smoking and impaired glu-
cose control was examined in many previous reports 
[16–18]. FBG levels were found to be higher in smok-
ers compared to non-smokers in the present study. 
Table 2. Antidiabetic drug usages among smoker and 
non-smoker patients
Non-smokers 
n (%)
Smokers 
n (%)
p
Anti-diabetic medications
0.920
Oral antidiabetic  
drugs
52 (37.1) 27 (38.6)
Insulin 36 (25.7) 19 (27.1)
Insulin and oral  
antidiabetic drugs
52 (37.1) 24 (34.3)
Table 1. Comparison of demographical and clinical features of smokers and non-smokers
Non-smoker Smoker p
Gender
Women, n (%) 90 (64.3%) 45 (64.3%) 1.000
Men, n (%) 50 (35.7%) 25 (35.7%)
Age (year) (MSD) 49.8 ± 14.7 49.4 ± 14.1 0.848
BMI [kg/m2] (MSD) 26.1 ± 3.7 26.5 ± 5.4 0.507
Diabetes duration (year) (MSD) 8.1 ± 5.90 8.5 ± 6 0.679
Exercise
No, n (%) 133 (95%) 61 (87.1%) 0.043
Yes, n (%) 7 (5%) 9 (12.9%)
Education
< High school, n (%) 63 (45%) 36 (51.4%) 0.038
≥ High school, n (%) 77 (55%) 34 (48.6%)
Diabetes education
No, n (%) 49 (35%) 16 (22.9%) 0.073
Yes, n (%) 91 (65%) 54 (77.1%)
Systolic blood pressure (MSD) 120.3 ± 12.9 124.5 ± 15.3 0.050
Diastolic blood pressure (MSD) 73.5 ± 10 79.5 ± 10.2 0.001
Fasting blood glucose [mg/dL] (MSD) 163.1 ± 59.1 193.5 ± 84.8 0.008
Postprandial blood glucose [mg/dL] (MSD) 252.8 ± 96.5 281.2 ± 114.3 0.061
HbA1c (%) (MSD) 8.8 ± 2 9.3 ± 2.3 0.133
Total cholesterol [mg/dL] (MSD) 179.9 ± 46.3 188.3 ± 46.7 0.216
LDL [mg/dL] (MSD) 102.2 ± 36.2 112.7 ± 33.4 0.042
HDL [mg/dL] (MSD) 41 ± 11.5 42.6 ± 13 0.382
TG [mg/dL] (MSD) 184.7 ± 134.4 171 ± 93 0.443
MSD — mean standard deviation; BMI — body mass ındex; HbA1c — glycated hemoglobin; LDL — low-density lipoprotein; TG — triglyceride; HDL — high-
-density lipoprotein
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In addition, PBG levels were higher in smokers whereas 
no statistically significant difference was found. Fur-
thermore, HbA1c levels were higher in smokers. This 
finding is inconsistent with other previous reports 
[16, 19]. All those increases could be partly explained 
by impaired glucose metabolism and insulin secretion 
due to smoking [20, 21].
It has been shown that achieving and maintaining 
glucose control is more difficult in smokers [16], hence 
microvascular complications can be more significant 
among diabetics who smoke. Smoking is one of the 
most important modifiable risk factors for the progres-
sion of microvascular complications and blood glucose 
dysregulation in diabetic patients. Smoking increases 
T2DM incidence and worsens T2DM complications. 
Although the mean HbA1c was significantly higher in 
current smokers, the difference between smokers and 
never-smokers in FBG and PBG was controversial in 
previous studies [16].
In our study, the prevalence of cigarette smoking 
among diabetic patients was found to be 33.3%. This 
ratio is comparable with smoking ratio among the 
Turks. According to WHO, one-third of Turkish adults 
smoke cigarettes [22].
Smoking immediately increases SBP and DBP due 
to an increased in sympathetic nervous system activi-
ties and released of epinephrine, norepinephrine and 
vasopressin hormones [23, 24]. However, smoking’s 
long term effect on blood pressure is not revealed [25]. 
Previous studies with older smokers found a larger 
difference in SBP compared to studies with younger 
smokers among T2DM patients [18]. It is an important 
outcome, considering that most of the smokers with 
T2DM were likely to be older. In this study, we found 
statistically significant differences in both DBP and SBP 
between smokers and non-smokers.
Previous studies indicated that smoking exerts a 
negative effect on lipid profiles [18, 26]. We found 
that LDL was significantly higher in smokers compared 
with non-smokers, as in previous reports [18]. Whereas, 
in HDL and TG statistically significant difference was 
not determined between smokers and non-smokers 
in our study.
One-third of T2DM patients have been diagnosed 
with microvascular complications at the time of 
diabetes diagnosis. However, the association between 
smoking and the development of microvascular com-
plications has not been fully elucidated [27].
Retinopathy takes years to develop but eventually 
appears in nearly all diabetic patients. Pathogenesis 
of diabetic retinopathy related smoking has not been 
clearly established, impaired retinal microcirculation 
may be implicated [28]. Previous studies of the as-
sociation between smoking and diabetic retinopathy 
had different results [28–30]. In our study, the presence 
of retinopathy rate was positively associated with the 
Table 3. Comparison of microvascular complications of 
smokers and non-smokers
Non-smokers 
n (%)
Smokers 
n (%)
p
Retinopathy
Negative 99 (70.7) 48 (68.6) 0.749
Positive 41 (29.3) 22 (31.4)
Nephropathy
Negative 86 (61.4) 36 (51.4) 0.166
Positive 54 (38.6) 34 (48.6)
Neuropathy
Negative 113 (80.7) 43 (61.4) 0.003
Positive 27 (19.3) 27 (38.6)
Table 4. Comparison of microvascular complications be-
tween smoking addiction levels
Nicotine dependence p
Low 
n (%)
Medium 
n (%)
High 
n (%)
Retinopathy
Negative 21 (91.3) 14 (60.9) 13 (54.2) 0.015
Positive  2 (8.7) 9 (39.1) 11 (45.8)
Nephropathy
Negative 15 (65.2) 10 (43.5) 11 (45.8) 0.268
Positive 8 (34.8) 13 (56.5) 13 (54.2)
Neuropathy
Negative 17 (73.9) 15 (65.2) 11 (45.8) 0.128
Positive 6 (26.1) 8 (34.8) 13 (54.2)
Table 5. Correlation of Fagerstrom Nicotine Depence Test 
score with clinical and laboratory features
r p
Age 0.082 0.5
BMI –0.244 0.042
Fasting blood glucose 0.247 0.039
Post prandial blood glucose 0.211 0.080
HbA1c 0.244 0.042
Total cholesterol –0.40 0.741
LDL 0.078 0.520
TG 0.043 0.724
HDL –0.183 0.128
BMI — body mass ındex; HbA1c — glycated hemoglobin; LDL — low-den-
sity lipoprotein; Tg — triglyceride; HDL — high-density lipoprotein
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Fagerström Test for Nicotine Dependence score. In 
addition, smokers have a higher rate of retinopathy 
than non-smokers, however, a statistically significant 
difference was not found. 
A previous meta-analysis indicated that smoking 
is associated with the prevalence and incidence of 
diabetic neuropathy [12]. This study revealed that neu-
ropathy has a significant difference between smokers 
and non-smokers, as in previous reports. Previous stud-
ies assessed that smoking is associated with diabetic 
nephropathy [9, 31]. Moreover, the smoking amount 
showed a dose-response relationship with albuminuria 
[31–33]. We also found that smokers have a higher rate 
of nephropathy comparing to non-smokers. However, 
the result was not statistically significant. 
We acknowledge that our study has several 
limitations. First of all, although our study was 
conducted in one of the largest hospitals in Ankara 
which admits average of 6000 patients per day, it is 
a mono-centered study and the number of subjects 
in this study was not large. Therefore the generali-
sability to other population groups is uncertain. 
Second, we enrolled only T2DM patients. Consequently, 
we did not have chance to evaluate our findings in dif-
ferent diabetic groups. Third, this is a cross-sectional 
analysis, precluding inference of causality to the ob-
served associations. The present findings should be 
replicated in a future study with a higher number of 
subjects, conducting a prospective assessment of each 
parameter. 
Conclusions
In conclusion; our results indicate that smokers 
with T2DM are more likely to have diabetic neuropa-
thy complication compared to non-smokers. In addi-
tion, the presence of retinopathy rate increased with 
increasing level of smoking addiction. Furthermore, 
the nicotine dependence test score were found to be 
positively correlated with HbA1c and FBG levels whereas, 
negatively correlated with body mass index among 
smokers. Those findings reaffirm the need for clinical 
research to test tailored smoking cessation interven-
tions for people with T2DM.
Smoking cessation might cause a reduction in 
microvascular complications. Unfortunately, there are 
limited data available to inform smoking cessation in 
people with diabetes. Therefore, it is thus of paramount 
importance to design intensive and innovative interven-
tions to quit smoking in T2DM. The potential benefits 
of giving up smoking in those patients should be tested 
and evaluated in future studies.
All diabetes care professionals should be aware of 
the addictive and harmful effects of smoking. 
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